Genentech Inc. and partner XOMA Ltd. won FDA approval for Raptiva, a biologic for psoriasis that can be self-administered once weekly on a continuous basis. (BioWorld Today)
Genentech Inc. and partner XOMA Ltd. won FDA approval for Raptiva, a biologic for psoriasis that can be self-administered once weekly on a continuous basis. (BioWorld Today)
Onyx Pharmaceuticals Inc. and partner Bayer Corp. initiated a pivotal Phase III study in renal cell carcinoma with BAY 43-9006, a cancer candidate considered by some to be one of the most exciting products in development. (BioWorld Today)
Onyx Pharmaceuticals Inc. and partner Bayer Corp. initiated a pivotal Phase III study in renal cell carcinoma with BAY 43-9006, a cancer candidate considered by some to be one of the most exciting products in development. (BioWorld Today)
Vertex Pharmaceuticals Inc. and partner GlaxoSmithKline plc won FDA approval of Lexiva, an HIV protease inhibitor that can be dosed once or twice daily, with or without food and water restrictions. (BioWorld Today)
